APA引文

Hardman, C., Chen, W., Luo, J., Batty, P., Chen, Y., Nahler, J., . . . Ogg, G. (2019). Fevipiprant, a selective prostaglandin D2 receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function. Elsevier.

芝加哥风格引文

Hardman, C., et al. Fevipiprant, a Selective Prostaglandin D2 Receptor 2 Antagonist, Inhibits Human Group 2 Innate Lymphoid Cell Aggregation and Function. Elsevier, 2019.

MLA引文

Hardman, C., et al. Fevipiprant, a Selective Prostaglandin D2 Receptor 2 Antagonist, Inhibits Human Group 2 Innate Lymphoid Cell Aggregation and Function. Elsevier, 2019.

警告:这些引文格式不一定是100%准确.